Zobrazeno 1 - 10
of 3 268
pro vyhledávání: '"ledipasvir"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andri Sanityoso Sulaiman, Irsan Hasan, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Gita Aprilicia, Yayah Nugroho, Nunuk Tri Wahyuni, Budiman Sujatmika Sulaiman
Publikováno v:
Jurnal Penyakit Dalam Indonesia, Vol 10, Iss 4, Pp 183-188 (2023)
Introduction. Direct-acting antivirals (DAAs) has been developed for treatment hepatitis C virus (HCV). Therapy of HCV using DAA has shown high sustained virologic response (SVR) and shortening duration of therapy. Sofosbuvir-ledipasvir (SOF/LDV) i
Externí odkaz:
https://doaj.org/article/4f85095e1e2040a09afb750be04fd5b6
Publikováno v:
Liver Research, Vol 7, Iss 4, Pp 361-364 (2023)
Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Curre
Externí odkaz:
https://doaj.org/article/6c43d2c02ba243b2967b3743565edd83
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Background Sofosbuvir/ledipasvir (SOF/LDV), a combination of antiviral drugs, has been recently repurposed for COVID-19 management, according to Food and Drug Administration approval. Paracetamol (PAR) identified as a first-line antipyretic
Externí odkaz:
https://doaj.org/article/8f79c964525b401fa7d8b129acd46234
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Background COVID-19 has emerged as the most serious outbreak in recent years. Certain medications such as sofosbuvir (SOF), ledipasvir (LDV) and paracetamol (PAR) were proposed as a safer and recommended substance to control symptoms of COVI
Externí odkaz:
https://doaj.org/article/1e1d92bc1cd54fd99ba28158463e7e1f
Autor:
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim
Publikováno v:
Medicina, Vol 60, Iss 7, p 1132 (2024)
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) followi
Externí odkaz:
https://doaj.org/article/dc00c24c45bd4ff8a14399e11147bffb
Autor:
Sergie Antoniak, Charles S Chasela, Morgan Julie Freiman, Yulia Stopolianska, Tetiana Barnard, Malini M Gandhi, Maria Liulchuk, Zhanna Tsenilova, Tretiakov Viktor, Jeri Dible, Constance Wose Kinge, Francis Akpan, Thomas Minior, Ntombi Sigwebela, Sofiane Mohamed, Matthiue Barralon, Fadzai Marange, Clint Cavenaugh, Charles Vander Horst, Svitlana Antonyak, Thembisile Xulu, Kara W Chew, Ian Sanne, Sydney Rosen, for EQUIP Health
Publikováno v:
JGH Open, Vol 6, Iss 12, Pp 894-903 (2022)
Abstract Background and Aim To demonstrate the use of a standard dose of ledipasvir (LDV) and sofosbuvir (SOF), with or without ribavirin, to treat hepatitis C and hepatitis C/HIV co‐infection in Ukraine. Methods Eligible HCV viraemic adults from t
Externí odkaz:
https://doaj.org/article/e28414838a3e4a78882d07b1520eb1f7
Autor:
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Publikováno v:
The Korean Journal of Internal Medicine, Vol 37, Iss 6, Pp 1167-1175 (2022)
Background/Aims To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting. Methods A total of 273 patients who received LDV/SOF therapy between May 20
Externí odkaz:
https://doaj.org/article/324246e4a849422781cf1509de5cce2e
Autor:
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hung, Te Sheng Chang, Jee-Fu Huang, Chi-Chieh Yang, Jui-Ting Hu, Chih-Wen Lin, Chun-Ting Chen, Chia-Chi Wang, Wei-Wen Su, Tsai-Yuan Hsieh, Chih-Lin Lin, Wei-Lun Tsai, Tzong-Hsi Lee, Guei-Ying Chen, Szu-Jen Wang, Chun-Chao Chang, Lein-Ray Mo, Sheng-Shun Yang, Wen-Chih Wu, Chia-Sheng Huang, Chou-Kwok Hsiung, Chien-Neng Kao, Pei-Chien Tsai, Chen-Hua Liu, Mei-Hsuan Lee, Chun-Jen Liu, Chia-Yen Dai, Wan-Long Chuang, Han-Chieh Lin, Jia-Horng Kao, Ming-Lung Yu
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 8, Pp 1567-1578 (2022)
Background/purpose: The Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) is a nationwide registry of chronic hepatitis C patients in Taiwan. This study evaluated antiviral effectiveness of ledipasvir (LDV)/sofosbuvir (SOF) in
Externí odkaz:
https://doaj.org/article/e3fc588ffb4644ea879b1c65ce5709a5